La chemioterapia con cisplatino e paclitaxel nel carcinoma della cervice localmente avanzato: Ha ancora un ruolo questo regime nella terapia neoadiuvante?

Translated title of the contribution: Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: Has this regimen still a role as neoadjuvant setting?

M. Moioli, A. Papadia, S. Mammoliti, E. Pacella, S. Menoni, M. V. Menada, N. Ragni

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim. Neoadjuvant chemotherapy represents a promising alternative to concomitant chemoradiation therapy in locally advanced cervical cancer patients. The aim of this study was the evaluation of pathologic response rates, toxicity and predictors of response in locally advanced cervical cancer patients treated with neoadjuvant cisplatin and paclitaxel followed by radical surgery. Methods. Fourteen patients with stage IB2 to HB cervical cancer received three cycles of cisplatin 75 mg/m 2 and paclitaxel 175 mg/m 2 intravenously every three weeks followed by radical hysterectomy and bilateral pelvic lymphadenectomy. Toxicity, pathologic response and predictors of response were evaluated. Results. Chemotherapy related toxicities were as follows: alopecia 100%, asthenia 35.7%; nausea and vomiting 14.3%; paclitaxel hypersensitivity 7.1%, neutropenia 7.1%. Optimal, partial and no pathologic response was achieved in 21.4%, 64.3% and 14.2% of the patients, respectively. Based on lack of pathologic risk factors, 43% of the patients did not receive any adjuvant radiotherapy. Better response rates were obtained in patients with stage IIB, tumor diameter 12 g/dL and SCC antigen

Original languageItalian
Pages (from-to)95-107
Number of pages13
JournalMinerva Ginecologica
Volume64
Issue number2
Publication statusPublished - Apr 2012

Fingerprint

Uterine Cervical Neoplasms
Drug Therapy
Paclitaxel
Asthenia
Adjuvant Radiotherapy
Alopecia
Neutropenia
Lymph Node Excision
Hysterectomy
Nausea
Cisplatin
Vomiting
TP protocol
Hypersensitivity
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

La chemioterapia con cisplatino e paclitaxel nel carcinoma della cervice localmente avanzato : Ha ancora un ruolo questo regime nella terapia neoadiuvante? / Moioli, M.; Papadia, A.; Mammoliti, S.; Pacella, E.; Menoni, S.; Menada, M. V.; Ragni, N.

In: Minerva Ginecologica, Vol. 64, No. 2, 04.2012, p. 95-107.

Research output: Contribution to journalArticle

@article{4ed819d4955448f797192fbedcbf7cb1,
title = "La chemioterapia con cisplatino e paclitaxel nel carcinoma della cervice localmente avanzato: Ha ancora un ruolo questo regime nella terapia neoadiuvante?",
abstract = "Aim. Neoadjuvant chemotherapy represents a promising alternative to concomitant chemoradiation therapy in locally advanced cervical cancer patients. The aim of this study was the evaluation of pathologic response rates, toxicity and predictors of response in locally advanced cervical cancer patients treated with neoadjuvant cisplatin and paclitaxel followed by radical surgery. Methods. Fourteen patients with stage IB2 to HB cervical cancer received three cycles of cisplatin 75 mg/m 2 and paclitaxel 175 mg/m 2 intravenously every three weeks followed by radical hysterectomy and bilateral pelvic lymphadenectomy. Toxicity, pathologic response and predictors of response were evaluated. Results. Chemotherapy related toxicities were as follows: alopecia 100{\%}, asthenia 35.7{\%}; nausea and vomiting 14.3{\%}; paclitaxel hypersensitivity 7.1{\%}, neutropenia 7.1{\%}. Optimal, partial and no pathologic response was achieved in 21.4{\%}, 64.3{\%} and 14.2{\%} of the patients, respectively. Based on lack of pathologic risk factors, 43{\%} of the patients did not receive any adjuvant radiotherapy. Better response rates were obtained in patients with stage IIB, tumor diameter 12 g/dL and SCC antigen",
keywords = "Chemotherapy, adjuvant, Hysterectomy, Uterine cervical neoplasms",
author = "M. Moioli and A. Papadia and S. Mammoliti and E. Pacella and S. Menoni and Menada, {M. V.} and N. Ragni",
year = "2012",
month = "4",
language = "Italian",
volume = "64",
pages = "95--107",
journal = "Minerva Ginecologica",
issn = "0026-4784",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - La chemioterapia con cisplatino e paclitaxel nel carcinoma della cervice localmente avanzato

T2 - Ha ancora un ruolo questo regime nella terapia neoadiuvante?

AU - Moioli, M.

AU - Papadia, A.

AU - Mammoliti, S.

AU - Pacella, E.

AU - Menoni, S.

AU - Menada, M. V.

AU - Ragni, N.

PY - 2012/4

Y1 - 2012/4

N2 - Aim. Neoadjuvant chemotherapy represents a promising alternative to concomitant chemoradiation therapy in locally advanced cervical cancer patients. The aim of this study was the evaluation of pathologic response rates, toxicity and predictors of response in locally advanced cervical cancer patients treated with neoadjuvant cisplatin and paclitaxel followed by radical surgery. Methods. Fourteen patients with stage IB2 to HB cervical cancer received three cycles of cisplatin 75 mg/m 2 and paclitaxel 175 mg/m 2 intravenously every three weeks followed by radical hysterectomy and bilateral pelvic lymphadenectomy. Toxicity, pathologic response and predictors of response were evaluated. Results. Chemotherapy related toxicities were as follows: alopecia 100%, asthenia 35.7%; nausea and vomiting 14.3%; paclitaxel hypersensitivity 7.1%, neutropenia 7.1%. Optimal, partial and no pathologic response was achieved in 21.4%, 64.3% and 14.2% of the patients, respectively. Based on lack of pathologic risk factors, 43% of the patients did not receive any adjuvant radiotherapy. Better response rates were obtained in patients with stage IIB, tumor diameter 12 g/dL and SCC antigen

AB - Aim. Neoadjuvant chemotherapy represents a promising alternative to concomitant chemoradiation therapy in locally advanced cervical cancer patients. The aim of this study was the evaluation of pathologic response rates, toxicity and predictors of response in locally advanced cervical cancer patients treated with neoadjuvant cisplatin and paclitaxel followed by radical surgery. Methods. Fourteen patients with stage IB2 to HB cervical cancer received three cycles of cisplatin 75 mg/m 2 and paclitaxel 175 mg/m 2 intravenously every three weeks followed by radical hysterectomy and bilateral pelvic lymphadenectomy. Toxicity, pathologic response and predictors of response were evaluated. Results. Chemotherapy related toxicities were as follows: alopecia 100%, asthenia 35.7%; nausea and vomiting 14.3%; paclitaxel hypersensitivity 7.1%, neutropenia 7.1%. Optimal, partial and no pathologic response was achieved in 21.4%, 64.3% and 14.2% of the patients, respectively. Based on lack of pathologic risk factors, 43% of the patients did not receive any adjuvant radiotherapy. Better response rates were obtained in patients with stage IIB, tumor diameter 12 g/dL and SCC antigen

KW - Chemotherapy, adjuvant

KW - Hysterectomy

KW - Uterine cervical neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84862745301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862745301&partnerID=8YFLogxK

M3 - Articolo

C2 - 22481620

AN - SCOPUS:84862745301

VL - 64

SP - 95

EP - 107

JO - Minerva Ginecologica

JF - Minerva Ginecologica

SN - 0026-4784

IS - 2

ER -